Kanglexin, a new anthraquinone compound, attenuates lipid accumulation by activating the AMPK/SREBP-2/PCSK9/LDLR signalling pathway

Xin Li,Xueling Hu,Tengfei Pan,Lei Dong,Lili Ding,Zhenzhong Wang,Rui Song,Xiuzhu Wang,Ning Wang,Yan Zhang,Jinhui Wang,Baofeng Yang
DOI: https://doi.org/10.1016/j.biopha.2020.110802
2021-01-01
Abstract:<p>Hyperlipidaemia is one of the major risk factors for atherosclerosis, coronary heart disease, stroke and diabetes. In the present study, we synthesized a new anthraquinone compound, 1,8-dihydroxy-3-succinic acid monoethyl ester-6-methylanthraquinone, and named it Kanglexin (KLX). The aim of this study was to evaluate whether KLX has a lipid-lowering effect and to explore the potential molecular mechanism. In this study, Sprague-Dawley rats were fed a high fat diet (HFD) for 5 weeks to establish a hyperlipidaemia model; then, the rats were orally administered KLX (20, 40, and 80 mg kg<sup>−1</sup>·d<sup>−1</sup>) or atorvastatin calcium (AT, 10 mg kg<sup>−1</sup>·d<sup>−1</sup>) once a day for 2 weeks. KLX had prominent effects on reducing blood lipids, hepatic lipid accumulation, body weight and the ratio of liver weight/body weight. Furthermore, KLXdramatically reduced the total cholesterol (TC) and triglyceride (TG) levels and lipid accumulation in a HepG2 cell model of dyslipidaemia induced by 1 mmol/L oleic acid (OA). KLX may decrease lipid levels by phosphorylating adenosine monophosphate-activated protein kinase (AMPK) and the downstream sterol regulatory element binding protein 2 (SREBP-2)/proprotein convertase subtilisin/kexin type 9 (PCSK9)/low-density lipoprotein receptor (LDLR) signalling pathway in the HFD rats and OA-treated HepG2 cells. The effects of KLX on the AMPK/SREBP-2/PCSK9/LDLR signalling pathway were abolished when AMPK was inhibited by compound C (a specific AMPK inhibitor) in HepG2 cells. In summary, KLX has an efficient lipid-lowering effect mediated by activation of the AMPK/SREBP-2/PCSK9/LDLR signalling pathway. Our findings may provide new insight into and evidence for the discovery of a new lipid-lowering drug for the prevention and treatment of hyperlipidaemia, fatty liver, and cardiovascular disease in the clinic.</p>
pharmacology & pharmacy,medicine, research & experimental
What problem does this paper attempt to address?
This paper aims to explore the effects of replacing grass silage (GS) with red clover silage (RCS) on nutrient digestion, nitrogen metabolism, and milk fat composition in dairy cows. Specifically, the study evaluates the impact of gradually increasing the proportion of red clover silage in the feed on milk yield, nutrient digestion, overall nitrogen metabolism, and milk fatty acid composition. The study found that although the increase in red clover silage raised the concentration of polyunsaturated fatty acids (PUFA) in the milk, it also reduced nitrogen utilization efficiency and had some impact on amino acid absorption and milk protein synthesis. Additionally, red clover silage altered the proportions of specific fatty acids in the milk, such as increasing the content of 18:2n-6 and 18:3n-3, while reducing the concentration of certain saturated fatty acids.